Antibodies to M-type phospholipase A2 receptor (a-PLA2R) have been identified in most patients with idiopathic membranous nephropathy, but the prevalence in membranous lupus nephritis (MLN) is still unclear. The objective of this study was to assess the prevalence of a-PLA2R antibodies in a large cohort of patients with lupus nephritis.
Methods
a-PLA2R antibodies were measured by ELISA in serum from patients with systemic lupus erythematosus (n = 190), of whom 37 had a biopsy-proven MLN. Positive samples were confirmed by commercial ELISA kit, Western blot and immunohistochemistry in renal tissue.
Results
A total of 10 from 190 patients (5.3%) with systemic lupus erythematosus had circulating a-PLA2R measured by in-house ELISA assay. The antibodies were detected in 7 patients with MLN (18.9%) and 3 patients with non-renal lupus disease (3.2%). PLA2R staining was detected in the kidney biopsy of 5 of the 7 (71.4%) patients with MLN. a-PLA2R levels were associated with active disease but not proteinuria levels. Presence of a-PLA2R antibodies at baseline was associated with worse remission rates and longer time to remission compared to those patients serologically negative.
Conclusions
a-PLA2R antibodies can be detected with low prevalence in MLN patients, but their detection is associated with a worse renal prognosis.
BoumpasDTAustinHAFesslerBJBalowJEKlippelJHLockshinMD. Systemic lupus erythematosus: emerging concepts. Part 1: renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease. Ann Intern Med1995; 122: 940–950.
2.
TsokosGCLoMsCosta ReisPSullivanKE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol2016; 12: 716–730.
3.
KewalramaniRSinghAK. Immunopathogenesis of lupus and lupus nephritis: recent insights. Curr Opin Nephrol Hypertens2002; 11: 273–277.
4.
RosnerSGinzlerEMDiamondHSet al.A multicentre study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum1982; 25: 612–617. .
KorbetSMMembranous lupus glomerulonephritis. In: LewisEJSchwartzMMKorbetSM (eds). Lupus nephritis, Oxford, UK: Oxford University Press, 1999, pp. 219–240.
7.
WeeningJJD'AgatiVDSchwartzMMet al.The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int2004; 65: 521–530.
8.
WardFBargmanJM. Membranous lupus nephritis: the same, but different. Am J Kidney Dis2016; 68: 954–966.
9.
DonadioJVJrBurgessJHHolleyKE. Membranous lupus nephropathy: a clinicopathologic study. Medicine1977; 56: 527–536.
10.
JennetteJCIskandarSSDalldorfFG. Pathologic differentiation between lupus and nonlupus membranous glomerulopathy. Kidney Int1983; 24: 377–385.
11.
NaWYiKSongYSParkMH. Dissecting the relationships of IgG subclasses and complements in membranous lupus nephritis and idiopathic membranous nephropathy. PLoS One2017; 12: e0174501.
12.
LinnikMDHuJZHeilbrunnKRet al.Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum2005; 52: 1129–1137.
13.
TrendelenburgMLopez-TrascasaMPotlukovaEet al.High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant2006; 21: 3115–3121. .
14.
GrootscholtenCDiekerJWMcGrathFDet al.A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Ann Rheum Dis2007; 66: 693–696. .
15.
SjöwallCZickertASkoghTWetteröJGunnarssonI. Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther2009; 11: R188.
16.
BeckLHJr. Membranous nephropathy and malignancy. Semin Nephrol2010; 30: 635–644.
17.
BeckLHJrBonegioRGLambeauGet al.M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med2009; 361: 11–21.
18.
GlassockRJ. Human idiopathic membranous nephropathy-A mystery solved?. N Engl J Med2009; 361: 81–83.
RoncoPDiebicH. Anti-phospholipase A2 receptor antibodies and the pathogenesis of membranous nephropathy. Nephron Clin Pract2014; 128: 232–237. .
21.
HofstraJMBeckLHJrBeckDMWetzelsJFSalantDJ. Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol2011; 6: 1286–1291.
22.
KanigicherlaDGummadovaJMcKenzieEAet al.Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int2013; 83: 940–948.
23.
TimmermansSAyalonRvan PaassenPet al.Anti-phospholipase A2 receptor antibodies and malignancy in membranous nephropathy. Am J Kidney Dis2013; 62: 1223–1225.
24.
LarsenCPMessiasNCSilvaFGMessiasEWalkerPD. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol2013; 26: 709–715.
25.
HuS-LWangDGouW-JLeiQ-FMaT-AChengJ-Z. Diagnostic value of phospholipase A2 receptor in idiopathic membranous nephropathy: a systematic review and meta-analysis. J Nephrol2014; 27: 111–116.
26.
GunnarssonISchlumbergerWRönnelidJ. Antibodies to M-type phospholipase A2 receptor (PLA2R) and membranous lupus nephritis. Am J Kidney Dis2012; 59: 585–586.
27.
SvobodovaBHonsovaERoncoPTesarVDebiecH. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy. Nephrol Dial Transplant2013; 28: 1839–1844.
28.
QinWBeckLHJrZengCet al.Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol2011; 22: 1137–1143.
29.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725.
GladmanDGinzlerEGoldsmithCet al.The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996; 39: 363–369. .
32.
AustinHA3rdMuenzLRJoyceKMet al.Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med1983; 75: 382–391.
33.
Cortés-HernándezJTorres-SalidoMTMedranoASTarrésMVOrdi-RosJ. Long-term outcomes—mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant2010; 25: 3939–3948.
34.
Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum2006; 54: 421–432.
35.
Lönnbro-WidgrenJEbeforsKMölneJNyströmJHaraldssonB. Glomerular IgG subclasses in idiopathic and malignancy-associated membranous nephropathy. Clin Kidney J2015; 8: 433–439.
36.
DongHRWangYYChengXHet al.Retrospective study of phospholipase A2 receptor and IgG subclasses in glomerular deposits in Chinese patients with membranous nephropathy. PLoS One2016; 11: 1–12.
37.
YanivGTwigGShorDBet al.A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. Autoimmun Rev2015; 14: 75–79.
38.
BechAPHofstraJMBrenchleyPEWetzelsJF. Association of anti-PLA2R antibodies with outcomes after immunosuppressive therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol2014; 9: 1386–1392.
39.
DebiecHRoncoP. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med2011; 364: 689–690.
40.
PourcineFDahanKMihoutFet al.Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: a single-centre study over 14 years. PLoS One2017; 12: e0173201.
41.
Segarra-MedranoAJatem-EscalanteECarnicer-CáceresCet al.Evolution of antibody titre against the M-type phospholipase A2 receptor and clinical response in idiopathic membranous nephropathy patients treated with tacrolimus. Nefrologia2014; 34: 491–497.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
